Amgen's Dazodalibep Shows Promise in Sjögren's Disease Trial

Amgen's experimental drug dazodalibep has shown promise in treating Sjögren's disease, a chronic autoimmune disorder affecting millions worldwide. The company announced that its late-stage study achieved statistically significant and clinically meaningful results after 48 weeks of treatment, with some patients experiencing improvements as early as week four.

The trial involved approximately 621 participants with moderate to severe Sjögren's, who reported common side effects such as nasal inflammation, urinary tract infections, high blood pressure, and infusion-related reactions. Despite these adverse events, Amgen's EVP Jay Bradner expressed confidence in the drug's potential, stating that it 'reinforces our confidence in dazodalibep'.

Analysts believe a second pivotal study is crucial to gauge the size of the effect, with completion expected by year-end. Citi analyst Geoff Meacham estimates the drug could generate up to $1.1 billion in annual revenue if it meets its goals. Sjögren's currently lacks FDA-approved therapies, making Amgen's breakthrough particularly significant.